Domantis Limited
Domantis Limited, Middlesex GB
Patent application number | Description | Published |
---|---|---|
20130041136 | LIGANDS THAT HAVE BINDING SPECIFICITY FOR EGFR AND/OR VEGF AND METHODS OF USE THEREFOR - Disclosed are ligands that have binding specificity for vascular endothelial growth factor (VEGF), for epidermal growth factor receptor (EGFR), or for VEGF and EGFR. Also disclosed are methods of using these ligands. In particular, the use of these ligands for cancer therapy is described. | 02-14-2013 |
Domantis Limited, Brentford GB
Patent application number | Description | Published |
---|---|---|
20130095109 | ANTIBODY POLYPEPTIDES THAT ANTAGONIZE CD40L - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single V | 04-18-2013 |
Domantis Limited US
Patent application number | Description | Published |
---|---|---|
20130216538 | Compositions and Methods for Treating Inflammatory Disorders - The invention relates to compositions and methods for treating inflammatory disorders. More specifically, the invention relates to antibody compositions and their use in the treatment of inflammatory disorders. | 08-22-2013 |
20140141093 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-TNFR1 polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for as therapeutics and/or prophylactics that are likely to encounter proteases when administered to a patient, for example for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating inflammatory disease, such as arthritis or COPD. | 05-22-2014 |